Allakos (ALLK) Competitors $0.33 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALLK vs. ATOS, CRBU, EXOZ, CRDL, IVVD, CTNM, BHST, CRBP, TNYA, and ANIXShould you be buying Allakos stock or one of its competitors? The main competitors of Allakos include Atossa Therapeutics (ATOS), Caribou Biosciences (CRBU), Exozymes (EXOZ), Cardiol Therapeutics (CRDL), Invivyd (IVVD), Contineum Therapeutics (CTNM), BioHarvest Sciences (BHST), Corbus Pharmaceuticals (CRBP), Tenaya Therapeutics (TNYA), and Anixa Biosciences (ANIX). These companies are all part of the "pharmaceutical products" industry. Allakos vs. Its Competitors Atossa Therapeutics Caribou Biosciences Exozymes Cardiol Therapeutics Invivyd Contineum Therapeutics BioHarvest Sciences Corbus Pharmaceuticals Tenaya Therapeutics Anixa Biosciences Allakos (NASDAQ:ALLK) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership and valuation. Does the MarketBeat Community believe in ALLK or ATOS? Atossa Therapeutics received 62 more outperform votes than Allakos when rated by MarketBeat users. Likewise, 65.68% of users gave Atossa Therapeutics an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformAllakosOutperform Votes18358.84% Underperform Votes12841.16% Atossa TherapeuticsOutperform Votes24565.68% Underperform Votes12834.32% Is ALLK or ATOS more profitable? Atossa Therapeutics' return on equity of -35.74% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets AllakosN/A -140.87% -86.22% Atossa Therapeutics N/A -35.74%-33.51% Which has more risk and volatility, ALLK or ATOS? Allakos has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Which has stronger earnings & valuation, ALLK or ATOS? Atossa Therapeutics is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllakosN/AN/A-$185.70M-$1.32-0.25Atossa TherapeuticsN/AN/A-$30.09M-$0.21-4.15 Do institutionals & insiders have more ownership in ALLK or ATOS? 84.6% of Allakos shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 16.1% of Allakos shares are owned by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend ALLK or ATOS? Allakos currently has a consensus price target of $2.00, suggesting a potential upside of 507.72%. Atossa Therapeutics has a consensus price target of $6.17, suggesting a potential upside of 607.51%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Atossa Therapeutics is more favorable than Allakos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media favor ALLK or ATOS? In the previous week, Atossa Therapeutics had 5 more articles in the media than Allakos. MarketBeat recorded 5 mentions for Atossa Therapeutics and 0 mentions for Allakos. Atossa Therapeutics' average media sentiment score of 0.87 beat Allakos' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Allakos Neutral Atossa Therapeutics Positive SummaryAtossa Therapeutics beats Allakos on 13 of the 16 factors compared between the two stocks. Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLK vs. The Competition Export to ExcelMetricAllakosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.74M$6.93B$5.60B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.168.8727.2520.01Price / SalesN/A263.25412.71157.94Price / CashN/A65.8538.2534.64Price / Book0.176.617.124.70Net Income-$185.70M$144.20M$3.24B$248.05M7 Day PerformanceN/A3.88%2.75%2.62%1 Month Performance-0.15%11.26%9.00%6.32%1 Year Performance-74.29%3.96%31.41%13.78% Allakos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLKAllakos3.9281 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190ATOSAtossa Therapeutics1.6401 of 5 stars$0.91+1.6%$6.17+574.6%-29.2%$118.07MN/A-4.168CRBUCaribou Biosciences3.0501 of 5 stars$1.27+0.8%$8.50+569.3%-39.2%$117.19M$9.92M-0.77100Analyst RevisionEXOZExozymesN/A$13.96+3.9%N/AN/A$116.82MN/A0.0029News CoverageGap DownCRDLCardiol Therapeutics2.3466 of 5 stars$1.44+2.1%$8.67+501.9%-51.0%$116.54MN/A-3.6920Gap UpIVVDInvivyd3.8169 of 5 stars$0.97-2.1%$5.85+504.2%-46.4%$116.15M$36.69M-0.49100Positive NewsGap DownCTNMContineum Therapeutics2.571 of 5 stars$4.48-5.7%$22.50+402.2%-71.3%$115.91M$50M-2.2731Positive NewsGap UpBHSTBioHarvest SciencesN/A$6.98+0.3%$13.67+95.8%N/A$114.65M$27.70M-5.59N/APositive NewsCRBPCorbus Pharmaceuticals4.1357 of 5 stars$9.21-0.2%$50.88+452.4%-82.2%$112.70MN/A-1.9640Positive NewsTNYATenaya Therapeutics3.7073 of 5 stars$0.69+8.1%$6.25+811.9%-82.9%$111.49MN/A-0.48110News CoverageHigh Trading VolumeANIXAnixa Biosciences3.4607 of 5 stars$3.40+23.2%$9.00+164.7%+30.2%$109.52M$210K-8.725Analyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Atossa Therapeutics Competitors Caribou Biosciences Competitors Exozymes Competitors Cardiol Therapeutics Competitors Invivyd Competitors Contineum Therapeutics Competitors BioHarvest Sciences Competitors Corbus Pharmaceuticals Competitors Tenaya Therapeutics Competitors Anixa Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLK) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLK Stock Free ALLK Stock Alerts